INTRODUCTION
The Eph (erythroprotein-producing hepatoma amplified sequence) receptor tyrosine kinase family is the largest family of tyrosine kinases and includes at least 14 Eph receptors and 8 ligands 1 . EphA1-A8 and 10 are sub-classified as EphA family members, whereas EphB1-B4 and B6 belong to the EphB family 2 .
EphA receptors generally bind the glycosylphosphatidylinositol (GPI)-linked ephrinA ligand EFNA1-5, whereas EphB receptors bind the transmembrane ephrin-B ligand EFNB1-3 3 . Both Eph receptors and ephrins localize to the cell surface. Upon Ephrin binding, Eph receptor undergo clustering, phosphorylation, kinase activation, followed by activation of downstream signaling cascades in both the receptor-and the ligand-expressing cells 4 .
The Eph/ephrin family is differentially expressed in various human tissues 5, 6, 7 .
They are involved in developmental processes, particularly in embryonic development, vasculature and nervous system 8, 9 . Recent evidence suggest that Eph receptors have both tumor promoting and suppressing activities depending on their expression pattern in different tumors. Some of the Eph/ephrin genes are oncogenic and highly expressed in human cancers including breast, colon, melanomas, lung cancer and prostate cancer 10, 11, 12, 13 .
On the other hand, Eph receptors have also been proposed to act as tumor suppressors 14, 15 . Loss-of-expression of Eph receptors is evident in some tumors, i.e., EphB2 and EphB4 in colorectal cancer, and EphB6 in breast cancer 16, 17, 18 . Knockout of EphB2 , EphB3 or EphA2 gene accelerates colorectal tumorigenesis or skin carcinogenesis in mouse models 14, 19 . Also, somatic gene For personal use only. on April 12, 2017 . by guest www.bloodjournal.org From mutation of EphB2 was identified in colorectal cancers and prostate tumors 20 . In addition, ectopic expression of EphB6 by transfection in neuroblastoma cells reduces cell growth in mouse xenografts 21 .
Aberrant CpG island (CGI) methylation can result in inactivation of tumor suppressor genes in cancer. Methylation of EphA2, EphA7, EphB2, EphB4 and EphB6 has been reported in several human solid tumors including colorectal, prostate and breast cancer 16, 17, 18, 22, 23 . However, hypermethylation and epigenetic regulation of Eph receptors and ephrins has not yet been investigated in hematological malignancies in detail.
We have recently used a methylated CpG island amplification (MCA) / DNA promoter microarray approach to genome-wide screen for hypermethylated CpG islands (CGIs) in acute lymphoblastic leukemia (ALL) 24 . Several Eph/Ephrin genes were identified as potentially targets of methylation by this screen. This prompted us to perform a comprehensive analysis of Eph/ephrin family members in ALL. Here, we demonstrate that 15 of Eph/ephrin family genes are frequently hypermethylated in leukemia cell lines and primary ALL samples. Also, we show that forced restoration of EphB4 expression induces apoptosis and suppresses cell growth in EphB4 hypermethylated cells. These results suggest that epigenetic silencing by hypermethylation of Eph/ephrin family genes contributes to ALL pathogenesis.
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MATERIALS AND METHODS

Cell lines and ALL patient samples
The following human leukemia cell lines were studied: of lymphoid origin: MOLT4, Jurkat, Peer, T-ALL1, CEM, J-TAG, B-JAB, RS4:11, ALL1, Raji, REH and Ramos . Of myeloid origen: K562, BV173, HL60, NB4, THP1, U937, OCI 
Bisulfate pyrosequencing and bisulfite sequencing
Bisulfite treatment of genomic DNA was performed as described 24 . Bisulfite pyrosequencing and bisulfite sequencing was performed as described 24 , 25 .
Primer sequences and conditions for bisulfite PCR and pyrosequencing are shown in Supplemental Table 2 .
RNA extraction and real-time PCR
RNA extraction, reverse transcription reactions and real-time PCR analysis were performed as described 24, 26 . Whole BM cDNA from normal control was purchased from Cell Systems (All Cells, LLC. Emeryville, CA). TaqMan probes were purchased from Applied Biosystems (Applied Biosystems, Foster City, CA).
5-Aza-2'-deoxycytidine and/or trichostatin A treatment
Leukemia cells were cultured in media supplemented with 2 μM 5-Aza-2'-deoxycytidine (DAC, Sigma, St, Louis, MO) daily for 4 days, 2 μM DAC for 4 days followed by 500 nM trichostatin A (TSA, ICN Biomedicals) for the last 24 hours, or 500 nM TSA for 24 hours alone as described 24 .
Luciferase assay
The EphB4 regulatory sequence from 512 bp upstream to 243 bp downstream of the EphB4 transcription start site (TSS) was cloned by genomic PCR using human genomic DNA as a template. Various size deletions of the promoter were generated, also by PCR, with various 5' primers and a fixed 3' primer (Supplemental Table 2 Luciferase activity was detected using a Dual Luciferase Assay System (Promega Co., Madison, WI). The ability to stimulate transcription was defined as the ratio of the luciferase activity in cells transfected with pGL3-#1, #2, #3, #4, or #5 relative to the activity in cells transfected with empty vector (pGL3-Basic). All experiments were repeated at least 3 times.
Lentivirus constructs and gene transduction
Human EphB4 lentiviral construct was generated by inserting human full length EphB4 cDNA into a lentiviral-CMV LTR-Ubiquitin-IRES-GFP transfer vector (FUGW), as described previously 26, 27 . In this vector, green fluorescent protein (GFP) is coexpressed with EphB4 in an internal ribosome entry site (IRES) expression cassette, and both are placed under the control of a cytomegalovirus (CMV) enhancer and ubiquitin promoter. Lentivirus production was conducted by co-transfection of 293T cells with lentiviral gene transfer vector carrying hEphB4
For personal use only. on April 12, 2017 . by guest www.bloodjournal.org From and lentivirus packaging plasmids as described 24 . For transduction of leukemia cells, cells were seeded at 1x10 5 cells/well in 6 well plates, and infected by adding 2 ml of viral supernatant supplemented with 4 μg/ml polybrene, as described 26 .
Cell growth and colony formation in soft agarose
Cell growth and colony formation assays was performed as previously described 24 .
Cell cycle and apoptosis analysis
Cell cycle analysis was performed using propidium iodide (PI) staining 24 .
Induction of apoptosis was quantified by measuring Annexin V-PE positive cells with flow cytometry using the Annexin VPE Apoptosis Detection Kit (BioVision, Mountain View, CA).
Immunoprecipitation and Western blot analysis
For Ephrin-B2 Fc stimulation, Raji/EphB4 and Raji/Vector cells were serum starved overnight and then stimulated with 3 μg/ml Ephrin-B2 Fc (R&D, Minneapolis MN) at the indicated time points. Cells were collected and lysed in RIPA buffer. Samples were analyzed by SDS-PAGE followed by Western blot analysis as previously described cDNA Microarray cDNA microarray analysis was performed at the MDACC Genomic Core Laboratory. Total RNA was isolated from Raji/EphB4 and Raji/Empty Vector cells. RNA amplification and labeling was performed as described 28, 29 . We hybridized Cy3-labeled RNA from Raji/Vector and Cy5-labeled RNA from
Raji/EphB4 on a cDNA microarray (manufactured by the Cancer Genomic Core Laboratory, MDACC) that contains 4704 genes. cDNA array results were filtered using the Filter on Fold Change option to identify genes up-regulated or downregulated 3 fold in tested samples.
Statistical analysis
Statistical analysis was performed using Prism 4 (GraphPad Software, Inc.) or values were 2-sided and P < 0.05 was considered statistically significant. Survival was calculated from initial presentation at MDACC using standard method.
RESULTS
Identification of hypermethylated Eph receptor and Ephrin family genes in leukemia cell lines
Using MCA/microarray, we identified six Eph receptor and ephrin genes (EphA5, 
Prevalence and clinical implications of Eph receptor and Ephrin gene methylation in primary ALL
We subsequently evaluated the methylation status of EphA2, A4, A5, A6, A7, A10, EphB1, B2, B3, B4, EFNA1, A3, A5, EFN B1 and B2 genes in pretreatment bone marrow samples obtained prior to any therapy from 64 patients with ALL.
Patient characteristics are shown in Supplemental Methylation density for each gene is shown in Figure 2 . Using a methylation density cut-off of 15%, methylation frequencies (percent of patients in which a gene is methylated) in ALL ranged from 18% to 96% ( Figure 1A&B ). Most genes were found frequently methylated, and in most cases two or more EphA-and EphB-receptors were found concomitantly methylated in patient samples (data not shown).
We further analyzed associations between gene methylation status and overall survival (OS) in ALL patients. To perform this exploratory analysis, patients were divided into three groups: those with methylation (≥15%) of 1-3 genes, 4 to 7 genes and 8 to 10 genes. The median survival of patients in the first group of patients had not been reached, whereas it was 120 weeks for the second group, and 48 weeks for the third group (p=0.048) ( Figure 2B ). This analysis cannot exclude that the survival effect observed is due to the presence of a hypermethylator phenotype instead of epigenetic inactivation of the genes analyzed here.
Expression of EphB4, EFNB2 and EFNA5 in leukemia cells and their responses to 5-aza-2'-deoxycitidine treatment
To examine the relationship between DNA methylation and gene expression, Figure 3D ). This suggest that restoration of EphB4 gene expression occurs via hypomethylation of the EphB4 DNA sequence. These data also indicate that the DNA methylation of these genes is associated with suppressed gene expression.
Role of DNA methylation on the promoter activity of EphB4
Because it is difficult to study all members of the Eph receptor/ephrin family in detail, we decided to focus on EphB4 since this gene was originally identified and abundantly expressed in human BM CD34+ cells 27 . To explore the potential role of EphB4 promoter methylation in silencing gene transcription, we designed 5 pairs of pyrosequencing assays each covering several CpG sites across the entire EphB4 promoter CpG island. We also performed bisulfite sequencing of region from -145 to +34 of the EphB4 promoter encompassing 18 CpG sites.
Methylation mapping by pyrosequencing and bisulfite sequencing revealed that EphB4 was methylated over its 1.2 Kb entire CGI in EphB4 negative Raji cells and in primary ALL samples but not in normal controls ( Figure 4A and data not shown). To determine whether hypermethylation of the CGI is associated with transcriptional silencing of the EphB4 gene, we tested the promoter activity of the EphB4 CGI in 293 T cells using 5 pGL3 luciferase reporter constructs containing serial deletion fragments of the EphB4 promoter ( Figure 4B ). We observed a remarkable increase in luciferase activity of constructs #1, #3, and #4, and greatly reduced luciferase activity of constructs #2 and #5 ( Figure 4B ). These results suggest that the CGI around EphB4 promoter, especially the region near 
Molecular mechanisms of EphB4 tumor suppression effect in Raji cells
To analyze global molecular changes following transduction of EphB4 in Raji cells, we performed a cDNA microarray analysis. When compared with Raji/empty vector cells, the Raji/EphB4 cells showed a different gene expression pattern. In fact, 292 genes were found up-regulated (supplemental table 3), whereas 170 were down-regulated after EphB4 transduction (supplemental Table   4 ). Further details on this analysis are shown in Supplemental Information. 
DISCUSSION
Using MCA/ microarray, we identified several Eph receptor and ephrin genes as potential hypermethylation targets in ALL patients. We further investigated the methylation profile of the entire Eph/ephrin family members in leukemia cell lines pathogenesis. This survival analysis should be considered as exploratory as we can not conclude that the survival effect observed is not due to a hypermethylation phenomenon instead of individual Eph/ephrine methylation.
Larger more detailed analysis will be needed to define these results. We also studied the molecular effect of EphB4 in Raji cells using a cDNA microarray. We identified a significant variation in about 462 transcripts (292 over-expression and 170 down-regulation) associated with the exogenous restoration of EphB4 expression. Interestingly, 64 genes whose putative function is that of a tumor suppressor were found as being up-regulated, and 54 genes whose function related to oncogenes were down-regulated. All these data 25  48  16  31  39  0  41  44  0  64  16  16  64  64  0  37  35   24  21  11  23  13  0  16  8  0  34  11  5  36  22  0  16 
Methylation Prevalence(%)
B
